EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Is Cardiac Transplantation Still a Contraindication in Patients with Muscular Dystrophy-Related End-Stage Dilated Cardiomyopathy? A Systematic Review

Luisa Politano iD

International Journal of Molecular Sciences · 13.05.2024 · 25 (10) · 5289

DOI: 10.3390/ijms25105289 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 13.05.2024. Verfasst von Luisa Politano. Beteiligte Einrichtung: Cardiomyology and Medical Genetics, University of Campania Luigi Vanvitelli, 80138 Naples, Italy. Hauptthemen laut MEDLINE: Cardiomyopathy, Dilated, Heart Transplantation, Muscular Dystrophies. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 220 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inherited muscular diseases (MDs) are genetic degenerative disorders typically caused by mutations in a single gene that affect striated muscle and result in progressive weakness and wasting in affected individuals. Cardiac muscle can also be involved with some variability that depends on the genetic basis of the MD (Muscular Dystrophy) phenotype. Heart involvement can manifest with two main clinical pictures: left ventricular systolic dysfunction with evolution towards dilated cardiomyopathy and refractory heart failure, or the presence of conduction system defects and serious life-threatening ventricular arrhythmias. The two pictures can coexist. In these cases, heart transplantation (HTx) is considered the most appropriate option in patients who are not responders to the optimized standard therapeutic protocols. However, cardiac transplant is still considered a relative contraindication in patients with inherited muscle disorders and end-stage cardiomyopathies. High operative risk related to muscle impairment and potential graft involvement secondary to the underlying myopathy have been the two main reasons implicated in the generalized reluctance to consider cardiac transplant as a viable option. We report an overview of cardiac involvement in MDs and its possible association with the underlying molecular defect, as well as a systematic review of HTx outcomes in patients with MD-related end-stage dilated cardiomyopathy, published so far in the literature.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, DilatedHeart TransplantationMuscular DystrophiesHumans

Stichwörter der Autor:innen

BMDDMDEDMDLGMDMFMsheart involvementlife expectancymolecular gene defects heart transplantationsurvival

Autor:innen und Institutionen

  • Cardiomyology and Medical Genetics, University of Campania Luigi Vanvitelli, 80138 Naples, Italy.

ORCID-Profile: Luisa Politano

Zitieren

APA

Politano, L. (2024). Is Cardiac Transplantation Still a Contraindication in Patients with Muscular Dystrophy-Related End-Stage Dilated Cardiomyopathy? A Systematic Review. International Journal of Molecular Sciences, 25(10), 5289. https://doi.org/10.3390/ijms25105289

Vancouver

Politano L. Is Cardiac Transplantation Still a Contraindication in Patients with Muscular Dystrophy-Related End-Stage Dilated Cardiomyopathy? A Systematic Review. International Journal of Molecular Sciences. 2024;25(10):5289. doi:10.3390/ijms25105289

BibTeX
@article{Politano2024,
  author = {Politano, Luisa},
  title = {Is Cardiac Transplantation Still a Contraindication in Patients with Muscular Dystrophy-Related End-Stage Dilated Cardiomyopathy? A Systematic Review},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {10},
  pages = {5289},
  doi = {10.3390/ijms25105289}
}
Kostenlos starten →